Squarepoint Ops LLC Buys Shares of 91,680 Kura Oncology, Inc. (NASDAQ:KURA)

Squarepoint Ops LLC acquired a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 91,680 shares of the company's stock, valued at approximately $799,000. Squarepoint Ops LLC owned approximately 0.12% of Kura Oncology as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of KURA. Virtus ETF Advisers LLC increased its holdings in shares of Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares during the last quarter. Harbor Advisors LLC acquired a new position in Kura Oncology in the fourth quarter worth $87,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the fourth quarter valued at $90,000. Corton Capital Inc. bought a new stake in Kura Oncology during the fourth quarter valued at $99,000. Finally, Optimize Financial Inc acquired a new stake in shares of Kura Oncology during the fourth quarter worth $100,000.

Wall Street Analyst Weigh In

Several research analysts have recently commented on KURA shares. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. UBS Group decreased their target price on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Mizuho dropped their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, May 19th. Finally, Wall Street Zen lowered Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $24.50.

Kura Oncology Stock Performance

Shares of KURA traded up $0.12 during mid-day trading on Tuesday, reaching $6.42. 1,600,526 shares of the company's stock traded hands, compared to its average volume of 1,210,280. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The business's 50-day moving average price is $6.09 and its 200-day moving average price is $7.84. The stock has a market capitalization of $555.81 million, a P/E ratio of -2.72 and a beta of 0.50. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million. Equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.